| MeSH term | MeSH ID | Detail |
|---|---|---|
| Breast Neoplasms | D001943 | 24 associated lipids |
| Lung Neoplasms | D008175 | 171 associated lipids |
| Pancreatic Neoplasms | D010190 | 77 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Mammary Neoplasms, Experimental | D008325 | 67 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
| Prostatic Neoplasms | D011471 | 126 associated lipids |
| Melanoma | D008545 | 69 associated lipids |
| Brain Diseases | D001927 | 27 associated lipids |
| Leukemia P388 | D007941 | 43 associated lipids |
| Hyperplasia | D006965 | 34 associated lipids |
| Leukemia | D007938 | 74 associated lipids |
| Leukemia, Myeloid | D007951 | 52 associated lipids |
| Bronchial Spasm | D001986 | 18 associated lipids |
| Lymphoma, B-Cell | D016393 | 24 associated lipids |
| Asthenia | D001247 | 5 associated lipids |
| Hypopharyngeal Neoplasms | D007012 | 1 associated lipids |
MAYTANSINE
MAYTANSINE is a lipid of Polyketides (PK) class. Maytansine is associated with abnormalities such as Myelosuppression and BOSLEY-SALIH-ALORAINY SYNDROME. The involved functions are known as Mutation, Agent, Polymerization, Cell Cycle Arrest and Drug Kinetics. Maytansine often locates in Cytoplasm, Hepatic, Lysosomes, Cell surface and Microtubules. The associated genes with MAYTANSINE are ABCB1 gene, HM13 gene, CNN1 gene, CYP2C8 gene and CYP2D6 gene. The related lipids are Valerates. The related experimental models are Xenograft Model.
Cross Reference
Introduction
To understand associated biological information of MAYTANSINE, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with MAYTANSINE?
MAYTANSINE is suspected in Myelosuppression, BOSLEY-SALIH-ALORAINY SYNDROME and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with MAYTANSINE
PubChem Associated disorders and diseases
What pathways are associated with MAYTANSINE
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with MAYTANSINE?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with MAYTANSINE?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with MAYTANSINE?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with MAYTANSINE?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with MAYTANSINE?
Xenograft Model
Xenograft Model are used in the study 'IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.' (Ab O et al., 2015).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with MAYTANSINE
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Géraud A et al. | Preliminary results of the concurrent use of radiotherapy for bone metastases and trastuzumab emtansine in patients with HER2-positive metastatic breast cancer. | 2016 | Cancer Radiother | pmid:27342941 |
| Dzimitrowicz H et al. | T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab. | 2016 | J. Clin. Oncol. | pmid:27298406 |
| Wang C et al. | Chromatography-based methods for determining molar extinction coefficients of cytotoxic payload drugs and drug antibody ratios of antibody drug conjugates. | 2016 | J Chromatogr A | pmid:27286648 |
| Hamblett KJ et al. | Altering Antibody-Drug Conjugate Binding to the Neonatal Fc Receptor Impacts Efficacy and Tolerability. | 2016 | Mol. Pharm. | pmid:27248573 |
| Ponte JF et al. | Understanding How the Stability of the Thiol-Maleimide Linkage Impacts the Pharmacokinetics of Lysine-Linked Antibody-Maytansinoid Conjugates. | 2016 | Bioconjug. Chem. | pmid:27174129 |
| Fan Y et al. | Effects of modulation of pentose-phosphate pathway on biosynthesis of ansamitocins in Actinosynnema pretiosum. | 2016 | J. Biotechnol. | pmid:27173582 |
| Jacot W et al. | Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases. | 2016 | Breast Cancer Res. Treat. | pmid:27167986 |
| Sandra K et al. | Multiple heart-cutting and comprehensive two-dimensional liquid chromatography hyphenated to mass spectrometry for the characterization of the antibody-drug conjugate ado-trastuzumab emtansine. | 2016 | J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. | pmid:27160547 |
| Milowsky MI et al. | Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer. | 2016 | Urol. Oncol. | pmid:27765518 |
| Walles M et al. | New Insights in Tissue Distribution, Metabolism, and Excretion of [3H]-Labeled Antibody Maytansinoid Conjugates in Female Tumor-Bearing Nude Rats. | 2016 | Drug Metab. Dispos. | pmid:27122302 |
| Ogitani Y et al. | DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1. | 2016 | Clin. Cancer Res. | pmid:27026201 |
| Baselga J et al. | Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer. | 2016 | Clin. Cancer Res. | pmid:26920887 |
| MartÃnez MT et al. | Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature. | 2016 | Crit. Rev. Oncol. Hematol. | pmid:26318092 |
| Force J et al. | Nodular Regenerative Hyperplasia After Treatment With Trastuzumab Emtansine. | 2016 | J. Clin. Oncol. | pmid:24778392 |
| T-DM1 Combo Graduates from I-SPY 2. | 2016 | Cancer Discov | pmid:27095360 | |
| Singh AP et al. | Evolution of Antibody-Drug Conjugate Tumor Disposition Model to Predict Preclinical Tumor Pharmacokinetics of Trastuzumab-Emtansine (T-DM1). | 2016 | AAPS J | pmid:27029797 |
| Shen K et al. | Safety and Efficacy of Trastuzumab Emtansine in Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: a Meta-analysis. | 2016 | Sci Rep | pmid:26979925 |
| Krop IE et al. | Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer. | 2016 | Breast Cancer Res. | pmid:26979312 |
| de Goeij BE and Lambert JM | New developments for antibody-drug conjugate-based therapeutic approaches. | 2016 | Curr. Opin. Immunol. | pmid:26963132 |
| Maass KF et al. | Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC Design. | 2016 | AAPS J | pmid:26912181 |
| Vankemmelbeke M and Durrant L | Third-generation antibody drug conjugates for cancer therapy--a balancing act. | 2016 | Ther Deliv | pmid:26893243 |
| Raja SM et al. | Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition. | 2016 | Oncotarget | pmid:26859680 |
| Kan S et al. | Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells. | 2015 | BMC Cancer | pmid:26475267 |
| Montero JC et al. | Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling. | 2015 | Oncotarget | pmid:26336133 |
| Gébleux R et al. | Antibody Format and Drug Release Rate Determine the Therapeutic Activity of Noninternalizing Antibody-Drug Conjugates. | 2015 | Mol. Cancer Ther. | pmid:26294742 |
| Storz U | Antibody-drug conjugates: Intellectual property considerations. | 2015 | MAbs | pmid:26292154 |
| Nguyen M et al. | Preclinical Efficacy and Safety Assessment of an Antibody-Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma. | 2015 | Clin. Cancer Res. | pmid:26240273 |
| Chung YC et al. | Caveolin-1 Dependent Endocytosis Enhances the Chemosensitivity of HER-2 Positive Breast Cancer Cells to Trastuzumab Emtansine (T-DM1). | 2015 | PLoS ONE | pmid:26172389 |
| Beerli RR et al. | Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency. | 2015 | PLoS ONE | pmid:26132162 |
| van Geel R et al. | Chemoenzymatic Conjugation of Toxic Payloads to the Globally Conserved N-Glycan of Native mAbs Provides Homogeneous and Highly Efficacious Antibody-Drug Conjugates. | 2015 | Bioconjug. Chem. | pmid:26061183 |
| Miranda Romero P and MarÃn Gil R | Trastuzumab emtansine in locally advanced or metastatic HER2 positive breast cancer; GENESIS-SEFH drug evaluation report. | 2015 | Farm Hosp | pmid:26005893 |
| Esteva FJ et al. | What Can We Learn about Antibody-Drug Conjugates from the T-DM1 Experience? | 2015 | Am Soc Clin Oncol Educ Book | pmid:25993162 |
| Hamblett KJ et al. | AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma. | 2015 | Mol. Cancer Ther. | pmid:25931519 |
| Yabe N et al. | [A Case of Advanced Breast Cancer in Which Marked Improvement of Joint Pain Was Obtained with Stepwise Dose Reduction of Trastuzumab Emtansine (T-DM1)]. | 2015 | Gan To Kagaku Ryoho | pmid:26805183 |
| Müller P et al. | Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade. | 2015 | Sci Transl Med | pmid:26606967 |
| Eisenstein M | Medicine: Eyes on the target. | 2015 | Nature | pmid:26580159 |
| Kan S et al. | Gemcitabine treatment enhances HER2 expression in low HER2-expressing breast cancer cells and enhances the antitumor effects of trastuzumab emtansine. | 2015 | Oncol. Rep. | pmid:25976081 |
| Dholaria B and Srinivasan S | T-DM1-related carotenoderma and hand-foot syndrome. | 2015 | Lancet | pmid:25933279 |
| Ahmed S et al. | HER2-directed therapy: current treatment options for HER2-positive breast cancer. | 2015 | Breast Cancer | pmid:25634227 |
| Foglietta J et al. | Letter to the editor concerning 'Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA'. | 2015 | Ann. Oncol. | pmid:25632067 |
| Wiggins B et al. | Characterization of cysteine-linked conjugation profiles of immunoglobulin G1 and immunoglobulin G2 antibody-drug conjugates. | 2015 | J Pharm Sci | pmid:25631158 |
| Lai KC et al. | Evaluation of Targets for Maytansinoid ADC Therapy Using a Novel Radiochemical Assay. | 2015 | Pharm. Res. | pmid:25630819 |
| Li T et al. | Improvement of ansamitocin P-3 production by Actinosynnema mirum with fructose as the sole carbon source. | 2015 | Appl. Biochem. Biotechnol. | pmid:25564203 |
| Carneiro BA et al. | Emerging therapeutic targets in bladder cancer. | 2015 | Cancer Treat. Rev. | pmid:25498841 |
| Mang Y et al. | Efficient elimination of CD103-expressing cells by anti-CD103 antibody drug conjugates in immunocompetent mice. | 2015 | Int. Immunopharmacol. | pmid:25467246 |
| Kalsi R et al. | Brain metastasis and response to ado-trastuzumab emtansine: a case report and literature review. | 2015 | Clin. Breast Cancer | pmid:25454740 |
| Sibaud V et al. | T-DM1-related telangiectasias: a potential role in secondary bleeding events. | 2015 | Ann. Oncol. | pmid:25403586 |
| Yamamoto H et al. | Phase I and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER2-positive metastatic breast cancer. | 2015 | Jpn. J. Clin. Oncol. | pmid:25332421 |
| Singh JC and Lichtman SM | Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients. | 2015 | Drugs Aging | pmid:26645293 |
| Hamblett KJ et al. | SLC46A3 Is Required to Transport Catabolites of Noncleavable Antibody Maytansine Conjugates from the Lysosome to the Cytoplasm. | 2015 | Cancer Res. | pmid:26631267 |